EuroBiotech: More Articles of Note


> ImmunOs raised CHF 15 million ($15 million) to complete first-in-human trials of a cancer drug. Pfizer Ventures co-led the series A with BioMedPartners. Release 

> Genmab shared early data on its CD3xCD20 bispecific. With dose escalation still ongoing, Genmab has seen a 37% response rate. Statement 

> Oryzon presented updated data on iadademstat in acute myeloid leukaemia. Three-quarters of patients have responded to the drug. Release 

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome trial. Analysts were expecting the data to drop imminently, but the results will remain blinded until after a meeting with the FDA. Statement 

> Oncopeptides published updated pivotal data on melflufen in multiple myeloma. The Swedish company is expected to file for approval next year. Release 

> Bioncotech Therapeutics detailed plans to test BO-112 in combination with Keytruda. Statement 

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.